Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-21 pm EDT 		5-day change 1st Jan Change
2.97 USD -1.00% Intraday chart for Century Therapeutics, Inc. -5.71% -10.54%
May. 10 Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting CI
May. 09 Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
AQ
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
GL
Century Therapeutics : Corporate Overview May 2024
PU
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
AQ
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
GL
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
AQ
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
GL
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GL
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
GL
Century Therapeutics : Corporate Overview March 2024
PU
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
AQ
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
GL
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
GL
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
GL
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
GL
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. News Century Therapeutics, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW